- Home
- IMNN vs NEUP Comparison
IMNN vs NEUP Comparison
Compare IMNN & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- NEUP
- Stock Information
- Founded
- IMNN 1982
- NEUP 1996
- Country
- IMNN United States
- NEUP United States
- Employees
- IMNN N/A
- NEUP N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- IMNN Health Care
- NEUP
- Exchange
- IMNN Nasdaq
- NEUP Nasdaq
- Market Cap
- IMNN 12.1M
- NEUP 12.7M
- IPO Year
- IMNN 1985
- NEUP N/A
- Fundamental
- Price
- IMNN $5.75
- NEUP $13.12
- Analyst Decision
- IMNN Buy
- NEUP Strong Buy
- Analyst Count
- IMNN 2
- NEUP 2
- Target Price
- IMNN $182.61
- NEUP $28.00
- AVG Volume (30 Days)
- IMNN 55.7K
- NEUP 77.3K
- Earning Date
- IMNN 11-06-2025
- NEUP 08-28-2025
- Dividend Yield
- IMNN N/A
- NEUP N/A
- EPS Growth
- IMNN N/A
- NEUP N/A
- EPS
- IMNN N/A
- NEUP 0.00
- Revenue
- IMNN N/A
- NEUP $15,662,715.00
- Revenue This Year
- IMNN N/A
- NEUP N/A
- Revenue Next Year
- IMNN N/A
- NEUP N/A
- P/E Ratio
- IMNN N/A
- NEUP $4.20
- Revenue Growth
- IMNN N/A
- NEUP N/A
- 52 Week Low
- IMNN $4.83
- NEUP $2.90
- 52 Week High
- IMNN $41.22
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- IMNN 36.86
- NEUP 63.02
- Support Level
- IMNN $5.53
- NEUP $11.35
- Resistance Level
- IMNN $5.89
- NEUP $15.14
- Average True Range (ATR)
- IMNN 0.32
- NEUP 1.65
- MACD
- IMNN 0.07
- NEUP 0.30
- Stochastic Oscillator
- IMNN 23.81
- NEUP 74.66
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.